A Prospective, Multicenter, Observational Study Evaluating Safety and Effectiveness of SAPIEN 3 Transcatheter Aortic Valve Replacement for Type-0 Bicuspid Aortic Valve Stenosis Patients in China
A legfontosabb adatok
- Ki végzi
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Hol
- Beijing (Kína)A helyszín megnézése
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 170 fő, tervezett
- Kezdés
- 2026. ápr. 15.
- Várható befejezés
- 2029. aug. 31.
- A vizsgálat típusa
- Megfigyeléses
- A vizsgált kezelések
- Transcatheter Aortic Valve Replacement
- A regiszteradat frissítve
- 2026. május 7.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults aged 50 or older in China with severe aortic stenosis and a Type-0 bicuspid aortic valve. They must be willing to have a SAPIEN 3 valve placed through a catheter (TAVR).
- Életkor
- 50 years or older
- Nem
- All sexes
- A betegség stádiuma
- Severe aortic stenosis (narrowing of the aortic valve), with or without symptoms. It is measured by heart ultrasound at rest: valve area ≤1.0 cm2 (or ≤0.6 cm2/m2), mean gradient ≥40 mm Hg, or peak speed ≥4.0 m/sec. People without symptoms need stricter values, an abnormal exercise test, or heart pumping (LVEF) <50%.
- Korábbi kezelés
- People who already have a mechanical or tissue replacement valve in any position cannot join.
- Biomarker vagy leletérték
- A CT scan (MDCT) must confirm a Type-0 bicuspid aortic valve. Blood vessels in the groin and pelvis must be wide enough for the device.
A részvétel fő kizáró okai
- Other valve types: unicuspid, Type-1 or Type-2 bicuspid, tricuspid or quadricuspid
- Need for open heart surgery, for example for other valve disease or complex coronary disease
- Weak heart pumping with LVEF < 30%, or unstable heart or breathing within 30 days
- Kidney replacement therapy (such as dialysis) at screening
- Expected survival under 12 months
A regiszter feltételei, szó szerint
Mind a 19 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥50 years, and after thorough physician-patient discussion and shared decision-making, willing to undergo or accept TAVR
- Severe AS, defined as follows:; For symptomatic patients: i) Aortic valve area ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), OR mean gradient ≥40 mm Hg, OR Maximal aortic valve velocity ≥4.0 m/sec by transthoracic echocardiography at rest b) For asymptomatic patients: i) Very severe AS with an aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), AND maximal aortic velocity ≥5.0 m/sec, or mean gradient ≥60 mm Hg by transthoracic echocardiography at rest, OR ii) Aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), AND a mean gradient ≥40 mm Hg or maximal aortic valve velocity ≥4.0 m/sec by transthoracic echocardiography at rest, AND an exercise tolerance test that demonstrates a limited exercise capacity, abnormal BP response, or arrhythmia OR iii) Aortic valve area of ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2), AND mean gradient ≥40 mmHg, or maximal aortic valve velocity ≥4.0 m/sec by transthoracic echocardiography at rest, AND a left ventricular ejection fraction <50%
- Type-0 bicuspid aortic valve anatomy confirmed by multi-detector computed tomography (MDCT)
- The subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits
- Adequate iliofemoral access and acceptable level of vessel calcification and tortuosity for safe device implant
- The study patient has provided written informed consent
Ki nem vehet részt
- Emergency interventional/surgical procedures within 30 days of the valve implant procedure
- Renal replacement therapy at the time of screening
- Currently participating in an investigational drug or another device study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials. Observational studies are not considered exclusionary
- Need for open heart surgery (including severe aortic regurgitation, mitral regurgitation or stenosis, or tricuspid regurgitation, congenital heart disease, AF, complex coronary artery disease)
- Hemodynamic or respiratory instability requiring inotropic support, mechanical ventilation or mechanical heart assistance within 30 days of the screening visit
- Cardiac imaging (echo, CT, and/or MRI) evidence of ventricular mass, thrombus or vegetation
- Ventricular dysfunction with LVEF < 30%
- Challenging calcification based on physician's experience and discretion
- Aortic valve is a congenital unicuspid valve, congenital Type-1 or Type-2 bicuspid valve, tricuspid or quadricuspid valve
- Severe femoral, iliac or aortic atherosclerosis, calcification, coarctation, aneurysm or tortuosity, which prevents transfemoral TAVR
- Pre-existing mechanical or bioprosthetic valve in any position
- Hypertrophic cardiomyopathy with obstruction
- Estimated life expectancy < 12 months
Helyszínek itt: Kína
- Chinese Academy of Medical Sciences, Fuwai Hospital, BeijingBeijing, KínaContact: Xiangbin Pan, MD.PhDToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
In China, bicuspid aortic valve (BAV) represents a significantly high proportion of the transcatheter aortic valve replacement (TAVR) population. The application of TAVR in patients with BAV is challenging due to complex anatomy. To date, no prospective study has evaluated the Sapien 3 TAVR in patients with Type-0 BAV.
A vizsgálat csoportja
- patients with Type-0 bicuspid aortic stenosis
patients with severe, calcific aortic stenosis and with Type-0 bicuspid anatomy confirmed by MDCT.
Kezelés: Transcatheter Aortic Valve Replacement
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. május 7.